AGI 134

Drug Profile

AGI 134

Alternative Names: AGI-134; Alpha-gal glycosphingolipid - BioLineRx; Beta-galactosidase glycosphingolipid - BioLineRx; Glycosphingolipid beta-galactosidase immunotherapy

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Agalimmune
  • Developer BioLineRx
  • Class Antineoplastics; Glycolipids; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 26 Mar 2018 BioLineRx has patents pending for AGI 134 in Europe, Japan, China, Canada, Australia and Israel
  • 26 Mar 2018 BioLineRx receives patent allowance for AGI 134 in USA
  • 01 Feb 2018 Pharmacodynamics data from a preclinical trial in Solid tumours released by BioLineRx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top